Payment overview · 2025
General Payments
$125.45
2 reported records · 2 companies
Healthcare provider profile · identity verified
Daniel Carl Lemkuil, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREEN BAY, WI · NPI 1730163437
Verified facts
What the public records show
CMS Open Payments records show Daniel Carl Lemkuil, MD received $125.45 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 86.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.89 | 86.8% | 1 | 2025 |
| True North Surgical Inc | Unresolved — no canonical attribution shown | $16.56 | 13.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.45 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $108.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1580 | 430 |
| Amlodipine Besylate | Amlodipine Besylate | 994 | 275 |
| Lisinopril | Lisinopril | 832 | 222 |
| Hydrochlorothiazide | Hydrochlorothiazide | 605 | 163 |
| Omeprazole | Omeprazole | 597 | 154 |
| Simvastatin | Simvastatin | 590 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 519 | 128 |
| Losartan Potassium | Losartan Potassium | 517 | 144 |
| Tamsulosin Hcl | Tamsulosin Hcl | 502 | 134 |
| Fluoxetine Hcl | Fluoxetine Hcl | 489 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 479 | 133 |
| Metformin Hcl | Metformin Hcl | 476 | 130 |
| Metoprolol Tartrate | Metoprolol Tartrate | 356 | 86 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 328 | 92 |
| Eliquis | Apixaban | 325 | 72 |
| Gabapentin | Gabapentin | 299 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 84 |
| Meloxicam | Meloxicam | 272 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 258 | 79 |
| Donepezil Hcl | Donepezil Hcl | 245 | 56 |
| Lorazepam | Lorazepam | 239 | 64 |
| Atenolol | Atenolol | 222 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 204 | 58 |
| Allopurinol | Allopurinol | 200 | 56 |
| Jardiance | Empagliflozin | 191 | 47 |
| Furosemide | Furosemide | 176 | 55 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 170 | 45 |
| Alprazolam | Alprazolam | 165 | 35 |
| Potassium Chloride | Potassium Chloride | 157 | 52 |
| Metformin Hcl Er | Metformin Hcl | 156 | 44 |
| Finasteride | Finasteride | 155 | 45 |
| Sertraline Hcl | Sertraline Hcl | 153 | 41 |
| Ezetimibe | Ezetimibe | 147 | 39 |
| Carvedilol | Carvedilol | 142 | 40 |
| Ozempic | Semaglutide | 137 | 29 |
| Warfarin Sodium | Warfarin Sodium | 133 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 37 |
| Tramadol Hcl | Tramadol Hcl | 127 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 67 |
| Memantine Hcl | Memantine Hcl | 122 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 29 |
| Trazodone Hcl | Trazodone Hcl | 104 | 30 |
| Aripiprazole | Aripiprazole | 103 | 30 |
| Lovastatin | Lovastatin | 103 | 29 |
| Alendronate Sodium | Alendronate Sodium | 102 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 101 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 32 |
| Prednisone | Prednisone | 84 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 13 |
| Xarelto | Rivaroxaban | 83 | 17 |
| Amoxicillin | Amoxicillin | 82 | 65 |
| Mirtazapine | Mirtazapine | 80 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 23 |
| Clonazepam | Clonazepam | 74 | 18 |
| Glipizide Er | Glipizide | 74 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 17 |
| Montelukast Sodium | Montelukast Sodium | 72 | 22 |
| Pregabalin | Pregabalin | 70 | 12 |
| Glipizide | Glipizide | 68 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 19 |
| Fenofibrate | Fenofibrate | 64 | 17 |
| Celecoxib | Celecoxib | 62 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 58 | 19 |
| Famotidine | Famotidine | 56 | 16 |
| Naproxen | Naproxen | 56 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 48 |
| Mounjaro | Tirzepatide | 51 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 34 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 20 |
| Valacyclovir | Valacyclovir Hcl | 45 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 11 |
| Trulicity | Dulaglutide | 42 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Latanoprost | Latanoprost | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 30 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 11 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 31 |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Indomethacin | Indomethacin | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 16 |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 12 |
| Nystatin | Nystatin | 22 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 11 |
| Invokana | Canagliflozin | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Verapamil Sr | Verapamil Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Testosterone | Testosterone | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125.45 · 2 records | Novo Nordisk Inc | Ozempic | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error